110 related articles for article (PubMed ID: 7531207)
1. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
Reichman RC; Morse GD; Demeter LM; Resnick L; Bassiakos Y; Fischl M; Para M; Powderly W; Leedom J; Greisberger C
J Infect Dis; 1995 Feb; 171(2):297-304. PubMed ID: 7531207
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
3. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
Demeter LM; Meehan PM; Morse G; Fischl MA; Para M; Powderly W; Leedom J; Holden-Wiltse J; Greisberger C; Wood K; Timpone J; Wathen LK; Nevin T; Resnick L; Batts DH; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):135-44. PubMed ID: 9768622
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
Been-Tiktak AM; Williams I; Vrehen HM; Richens J; Aldam D; van Loon AM; Loveday C; Boucher CA; Ward P; Weller IV; Borleffs JC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2664-8. PubMed ID: 8913487
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
Kleim JP; Winters M; Dunkler A; Suarez JR; Riess G; Winkler I; Balzarini J; Oette D; Merigan TC
J Infect Dis; 1999 Mar; 179(3):709-13. PubMed ID: 9952383
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
[TBL] [Abstract][Full Text] [Related]
9. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
[TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Davey RT; Chaitt DG; Reed GF; Freimuth WW; Herpin BR; Metcalf JA; Eastman PS; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Boyle J; Coleman S; Cox SR; Wathen L; Daenzer CL; Lane HC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1657-64. PubMed ID: 8807058
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex.
Brew BJ; Dunbar N; Druett JA; Freund J; Ward P
AIDS; 1996 Oct; 10(12):1357-60. PubMed ID: 8902064
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.
Been-Tiktak AM; Vrehen HM; Schneider MM; van der Feltz M; Branger T; Ward P; Cox SR; Harry JD; Borleffs JC
Antimicrob Agents Chemother; 1995 Mar; 39(3):602-7. PubMed ID: 7793859
[TBL] [Abstract][Full Text] [Related]
16. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
[TBL] [Abstract][Full Text] [Related]
19. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
20. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
Saag MS; Emini EA; Laskin OL; Douglas J; Lapidus WI; Schleif WA; Whitley RJ; Hildebrand C; Byrnes VW; Kappes JC
N Engl J Med; 1993 Oct; 329(15):1065-72. PubMed ID: 7690462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
